Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0017349,
umls-concept:C0026377,
umls-concept:C0085732,
umls-concept:C0205161,
umls-concept:C0205307,
umls-concept:C0206431,
umls-concept:C0221099,
umls-concept:C0282641,
umls-concept:C0441889,
umls-concept:C0456387,
umls-concept:C0567416,
umls-concept:C0596988,
umls-concept:C1171362,
umls-concept:C1442161,
umls-concept:C1515670,
umls-concept:C2700640
|
pubmed:issue |
3
|
pubmed:dateCreated |
1992-8-25
|
pubmed:abstractText |
Successive transfers of HLA-DR alpha and beta genes restored expression of HLA-DR antigens to human B-lymphoblastoid cell line, LCL .174, from which all known expressible class II genes are deleted. While transferent cells displayed large amounts of DR on their surfaces, transgene-encoded DR3 molecules lacked a conformation-dependent epitope. DR1-restricted CTL lysis of DR1-expressing transferents pulsed with native influenza virus proteins was greatly reduced; the same cells were efficiently lysed in the presence of CTL-recognized influenza peptides. The properties of DR-expressing transferents of .174 suggest they are defective in producing peptides from exogenous proteins or in forming DR/peptide complexes. Comparison with other DR-expressing deletion mutants indicates that at least one gene in an approximately 230 kb DNA segment between the DQ1 and Ring 7 loci is needed for normal DR-mediated processing and presentation. Production of DR3 molecules having the conformation-dependent 16.23 epitope and efficient DR1-restricted presentation of influenza viral epitopes occurred in a B cell line that has a mutation specifically eliminating expression of the TAP1 transporter gene, which is in the approximately 230 kb interval and is needed for production of HLA class I/peptide complexes.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0022-1767
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
149
|
pubmed:geneSymbol |
HLA-DR
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
754-61
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1634767-Antibodies, Monoclonal,
pubmed-meshheading:1634767-Antigen-Presenting Cells,
pubmed-meshheading:1634767-Carrier Proteins,
pubmed-meshheading:1634767-Chromosome Deletion,
pubmed-meshheading:1634767-Genes, MHC Class II,
pubmed-meshheading:1634767-HLA-DR Antigens,
pubmed-meshheading:1634767-Humans,
pubmed-meshheading:1634767-Major Histocompatibility Complex,
pubmed-meshheading:1634767-Mutation,
pubmed-meshheading:1634767-Protein Conformation,
pubmed-meshheading:1634767-Transfection
|
pubmed:year |
1992
|
pubmed:articleTitle |
MHC class II deletion mutant expresses normal levels of transgene encoded class II molecules that have abnormal conformation and impaired antigen presentation ability.
|
pubmed:affiliation |
Department of Genetics, University of Wisconsin, Madison 53706.
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, U.S. Gov't, P.H.S.
|